Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Diabetes Drug May Reverse Alzheimer's and Enters Major Clinical Trial

Published: Tuesday, September 17, 2013
Last Updated: Tuesday, September 17, 2013
Bookmark and Share
A commonly prescribed diabetes drug could reverse memory loss and the build-up of plaques on the brain linked to Alzheimer's.

The research is published in Neuropharmacology. The findings come as the charity prepares the next phase of its Drug Discovery programme which aims to repurpose existing drugs as dementia treatments in as little as five to ten years.

Results from the study, led by Professor Christian Hölscher at Lancaster University, show that liraglutide might be able to reverse some of the damage caused by Alzheimer's disease in the later stages of the condition. Mice with late-stage Alzheimer's given the drug performed significantly better on an object recognition test and their brains showed a 30 per cent reduction in the build-up of toxic plaques.

Liraglutide is a member of a class of drugs known as a GLP-1 analogue. The drug is used to stimulate insulin production in diabetes, but research shows it can also pass through the blood brain barrier and have a protective effect on brain cells.

Alzheimer's Society's flagship Drug Discovery programme seeks to repurpose existing drugs for use in dementia. An earlier study of liraglutide funded by the charity showed promising results in mice with early stage Alzheimer's. This research now demonstrates the drug's potential as a treatment in the later stages of the condition. A major clinical trial led by Dr Paul Edison of Imperial College London and partly funded by Alzheimer's Society to test the effectiveness of the drug in people with Alzheimer's disease will also begin recruiting patients in the next few weeks.

Alzheimer's disease is the most common form of dementia. The condition is caused by diseases of the brain and is characterised by the slow death of brain cells. It is progressive, there are few effective treatments and as yet there is no cure. If successful in clinical trials liraglutide will be the first new dementia treatment in a decade.

Dr Doug Brown, Director of Research and Development at Alzheimer's Society said:

'Developing new drugs from scratch can take 20 years and hundreds of millions of pounds. We owe it to the 800,000 people with dementia in the UK to do everything we can to accelerate the process. Our focus on repurposing existing drugs as dementia treatments is an incredibly exciting way of bringing new treatments closer.

This exciting study suggests that one of these drugs can reverse the biological causes of Alzheimer's even in the late stages and demonstrates we're on the right track. We're now funding a major new trial to bring it closer to a position where it can be improving the lives of people with dementia.'


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,500+ scientific posters on ePosters
  • More Than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
The Changing Tides of the In Vitro Diagnostics Market
With the increasing focus in personalized medicine, diagnostics plays a crucial role in patient monitoring.
LaVision BioTec Reports on the Neuro Research on the Human Brain After Trauma
Company reports on the work of Dr Ali Ertürk from the Institute for Stroke and Dementia Research at LMU Munich.
NIH Study Shows No Benefit of Omega-3 Supplements for Cognitive Decline
Research was published in the Journal of the American Medical Association.
Less May Be More in Slowing Cholera Epidemics
Mathematical model shows more cases may be prevented and more lives saved when using one dose of cholera vaccine instead of recommended two doses.
Investigating the Vape
Expert independent review concludes that e-cigarettes have potential to help smokers quit.
NIH Launches Human RSV Study
Study aims to understand infection in healthy adults to aid development of RSV medicines, vaccines.
Researchers Discover Synthesis of a New Nanomaterial
Interdisciplinary team creates biocomposite for first time using physiological conditions.
Poor Survival Rates in Leukemia Linked to Persistent Genetic Mutations
For patients with an often-deadly form of leukemia, new research suggests that lingering cancer-related mutations – detected after initial treatment with chemotherapy – are associated with an increased risk of relapse and poor survival.
Flu Remedies Help Combat E. coli Bacteria
Physiologists from the University of Zurich have now discovered why the intestinal bacterium Escherichia coli (E. coli) multiplies heavily and has an inflammatory effect.
Marijuana Genome Unraveled
A study by Canadian researchers is providing a clearer picture of the evolutionary history and genetic organization of cannabis, a step that could have agricultural, medical and legal implications for this valuable crop.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!